Get access to our best features
Get Started
Subscribe
Israel-Hamas Conflict
Donald Trump
US Economy
Joe Biden
US Politics
Baseball
Republican Party
US Crime
Golf
PGA Championship
Memorial Day
Michael Cohen
Department of Justice
Get access to our best features
Get Started
Published 2 years ago

Bharat Biotech Seeks DCGI Nod for Covaxin Booster Trial Among Children Aged 2 to 18

Summary by Ground News
Hyderabad-based pharma company Bharat Biotech has sought permission from the Drugs Controller General of India (DCGI) to conduct trials of Covaxin as COVID-19 vaccine booster dose. The company has applied for permission a week ago. It has already conducted trials in the age group of 2-18 for two doses of CovXin.

0 Articles

All
Left
Center
Right
News18 IndiaNews18 India

Bharat Biotech Seeks DCGI Nod for Covaxin Booster Trial Among Children Aged 2 to 18

The precaution dose of Covaxin and Covishield is being administered to all those above 18 years old and have completed nine months after the second dose

2 years ago·India
Read Full Article
India TodayIndia Today

Bharat Biotech seeks DCGI nod for booster trial of Covaxin among kids aged 2-18 years

Bharat Biotech has sought DCGI’s approval to conduct phase 2/3 trial of its Covid-19 vaccine Covaxin as a booster shot among children aged 2-18 years old.

2 years ago·India
Read Full Article
LatestlyLatestly

COVID-19 Vaccine Precaution Dose: Bharat Biotech Seeks DCGI's Permission to Conduct Covaxin Booster Trials in 2-18 Age Group

Bharat Biotech has also applied for the EUA for the 2-5 years old but Subject Expert Committee (SEC) has asked for more data. Bharat Biotech is the first company in India who had applied for permission from DCGI to conduct trials of a booster dose in the 2-18 age group. COVID-19 Vaccine Precaution Dose: Bharat Biotech Seeks DCGI's Permission to Conduct Covaxin Booster Trials in 2-18 Age Group.

2 years ago
Read Full Article
Ommcom NewsOmmcom News

Bharat Biotech Seeks Nod For Covaxin Booster Trials For 2-18 Age Group

New Delhi:  Hyderabad-based vaccine manufacturer Bharat Biotech has sought permission to conduct booster dose trials of its Covid vaccine Covaxin for below 18 population. According to a source, Bharat Biotech has sought approval from apex drug regulator Drug Controller General of India to conduct a Phase 2/3 study of Covaxin as a booster dose for […]The post Bharat Biotech Seeks Nod For Covaxin Booster Trials For 2-18 Age Group appeared first on…

2 years ago·Bhubaneswar, India
Read Full Article
MoneycontrolMoneycontrol

Bharat Biotech seeks DCGI nod for phase 2/3 Covaxin booster trial among two to 18-year-old

Presently, precaution dose of Covaxin and Covishield is administered to all those aged above 18 who have completed nine months after the second dose.

2 years ago·India
Read Full Article
The Free Press JournalThe Free Press Journal

Bharat Biotech seeks DCGI's permission to conduct Covaxin booster trials in 2-18 age group

Hyderabad-based pharma company Bharat Biotech has sought permission from the Drugs Controller General of India (DCGI) to conduct trials of Covaxin as COVID-19 vaccine booster dose in the 2-18 age group, sources said.

2 years ago·Mumbai, India
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe
Ground News Article Assistant
Not enough coverage to generate an Article Assistant.

Bias Distribution

  • 100% of the sources lean Right
100% Right
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

VaccinesVaccines
CoronavirusCoronavirus
Trending Topics
Ground News logo
US
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc.
News
For You
Search
BlindspotLocal